CA2535401C - Composition emulsionnee contenant de la dapsone - Google Patents
Composition emulsionnee contenant de la dapsone Download PDFInfo
- Publication number
- CA2535401C CA2535401C CA2535401A CA2535401A CA2535401C CA 2535401 C CA2535401 C CA 2535401C CA 2535401 A CA2535401 A CA 2535401A CA 2535401 A CA2535401 A CA 2535401A CA 2535401 C CA2535401 C CA 2535401C
- Authority
- CA
- Canada
- Prior art keywords
- percent
- dapsone
- emulsive
- emulsive composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La présente invention a trait à un composition topique émulsionnée contenant de la dapsone ou de son dérivé. La composition selon l'invention comporte des émollients et de la dapsone ou son dérivé dans une émulsion stable. La stabilité est réalisée grâce à l'utilisation d'une combinaison de certains mélanges de tensioactifs et à d'un activateur assurant une solubilité de la dapsone.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49491203P | 2003-08-13 | 2003-08-13 | |
US60/494,912 | 2003-08-13 | ||
PCT/US2004/026447 WO2005016296A1 (fr) | 2003-08-13 | 2004-08-13 | Composition emulsionnee contenant de la dapsone |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2535401A1 CA2535401A1 (fr) | 2005-02-24 |
CA2535401C true CA2535401C (fr) | 2011-07-26 |
Family
ID=34193253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2535401A Active CA2535401C (fr) | 2003-08-13 | 2004-08-13 | Composition emulsionnee contenant de la dapsone |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1675563A4 (fr) |
JP (1) | JP2007533606A (fr) |
AU (1) | AU2004264964A1 (fr) |
CA (1) | CA2535401C (fr) |
MX (1) | MXPA06001713A (fr) |
WO (1) | WO2005016296A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008351422A1 (en) * | 2008-02-27 | 2009-09-03 | Allergan, Inc. | Dapsone to treat rosascea |
CN105246457B (zh) * | 2012-11-20 | 2019-06-07 | 阿勒根公司 | 局部氨苯砜和氨苯砜/阿达帕林组合物及其使用方法 |
AU2019281888B2 (en) * | 2018-06-04 | 2024-05-02 | Arcutis Biotherapeutics Inc | Method and formulation for improving roflumilast skin penetration lag time |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721242A (en) * | 1993-06-17 | 1998-02-24 | Hoffmann-La Roche Inc. | Antibiotic combination |
US5863560A (en) * | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
US20030157036A1 (en) * | 2002-02-20 | 2003-08-21 | Osborne David W. | Topical dapsone for the treatment of acne |
FR2753626B1 (fr) * | 1996-09-20 | 1998-11-06 | Centre International De Rech Dermatologiques Galderma Cird Galderma | Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant |
US6372234B1 (en) * | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US6056955A (en) * | 1999-09-14 | 2000-05-02 | Fischetti; Vincent | Topical treatment of streptococcal infections |
-
2004
- 2004-08-13 JP JP2006523427A patent/JP2007533606A/ja active Pending
- 2004-08-13 WO PCT/US2004/026447 patent/WO2005016296A1/fr active Search and Examination
- 2004-08-13 MX MXPA06001713A patent/MXPA06001713A/es not_active Application Discontinuation
- 2004-08-13 EP EP04781175A patent/EP1675563A4/fr not_active Withdrawn
- 2004-08-13 AU AU2004264964A patent/AU2004264964A1/en not_active Abandoned
- 2004-08-13 CA CA2535401A patent/CA2535401C/fr active Active
Also Published As
Publication number | Publication date |
---|---|
WO2005016296A1 (fr) | 2005-02-24 |
JP2007533606A (ja) | 2007-11-22 |
EP1675563A1 (fr) | 2006-07-05 |
EP1675563A4 (fr) | 2009-07-15 |
MXPA06001713A (es) | 2007-01-26 |
AU2004264964A1 (en) | 2005-02-24 |
CA2535401A1 (fr) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060204526A1 (en) | Emulsive composition containing Dapsone | |
AU647922B2 (en) | Improvements in or relating to organic compounds | |
JP3863111B2 (ja) | 半透明のナノエマルジョン、その製造方法及び、化粧品、皮膚科、及び/または眼科におけるその使用 | |
DE60105362T2 (de) | Wässrige kosmetische gele | |
US20090053146A1 (en) | Metronidazole-based dermatological foams and emulsions for the preparation thereof | |
US6121314A (en) | Pharmaceutical composition | |
WO2009129627A1 (fr) | Nouvelles compositions de resvératrol | |
US5653989A (en) | Water-in oil lotion containing corticosteroid | |
US20100151054A1 (en) | Emulsion lotion | |
US10561627B2 (en) | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films | |
CN101048136B (zh) | 微乳化和亚微米乳化方法和组合物 | |
US20100004338A1 (en) | Topical gel composition comprising azelaic acid | |
US20090221625A1 (en) | Cosmeceutical composition | |
CA2535401C (fr) | Composition emulsionnee contenant de la dapsone | |
US20010029266A1 (en) | Composition containing a pentacyclic triterpenic acid, method | |
JP5141017B2 (ja) | O/wエマルション組成物 | |
US20170348261A1 (en) | Medical dermatological preparation for external use | |
US20220331238A1 (en) | Oil-in-water emulsion of mometasone | |
US20080075745A1 (en) | Topical pharmaceutical compositions containing ciclopirox or a pharmaceutically acceptable salt thereof | |
JP5061519B2 (ja) | 抗真菌剤含有o/wエマルション組成物 | |
US11007161B1 (en) | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films | |
JPH06239740A (ja) | ミコフェノール酸含有外用治療薬 | |
JP2023006915A (ja) | 半透明乃至透明の皮膚外用剤 | |
JP5061518B2 (ja) | アモロルフィン含有o/wエマルション組成物 | |
JP2023006123A (ja) | 水中油型乳化組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |